Clinical Trial Update: Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides [Phase 3]

View source ↗

Summary

A Phase 3 multicenter, randomized, double-blind trial evaluated whether rosuvastatin affects subclinical markers of atherosclerosis in patients with ANCA-associ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: ANCA-associated Primary Necrotizing Vasculitides | Phase 3 | Status: COMPLETED